| Literature DB >> 24858998 |
Misi He1, Yu Li2, Li Zhang1, Longjiang Li1, Yi Shen1, Ling Lin1, Weiping Zheng3, Li Chen3, Xiuwu Bian4, Ho-Keung Ng5, Li Tang1.
Abstract
Recently, the survival rate of medulloblastoma patients has greatly improved; yet, patients undergoing current treatment regimes suffer from serious therapy-related side-effects. The aim of the present study was to investigate the anticancer effects of curcumin on medulloblastoma cells by testing its capacity to suppress proliferation and regulate the Wnt/β-catenin pathway. In the present study, cell proliferation was determined by MTT assay. Cell cycle was observed by flow cytometry. The changes in the Wnt/β-catenin pathway were analyzed by immunofluorescence, western blot analysis and RT-PCR. Curcumin treatment resulted in a dose- and time-dependent inhibition of proliferation in the medulloblastoma cell line. Curcumin treatment arrested the cell-cycle at the G2/M phase. Furthermore, curcumin treatment led to activation of GSK-3β, reduced expression of β-catenin and its downstream target cyclin D1. The attenuation of the Wnt/β‑catenin pathway was due to the loss of nuclear β-catenin. In conclusion, curcumin can inhibit cell growth by suppressing the Wnt/β-catenin signaling pathway, and it has the potential to be developed as a therapeutic agent for medulloblastoma.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24858998 DOI: 10.3892/or.2014.3206
Source DB: PubMed Journal: Oncol Rep ISSN: 1021-335X Impact factor: 3.906